EU Orders Supplies of GSK’s Experimental COVID-19 Drug
The EU has ordered up to 220,000 doses of sotrovimab, an investigational monoclonal antibody developed by GlaxoSmithKline and Vir Biotechnology to supply up to 220,000 doses of sotrovimab, their investigational COVID-19 therapy.
The monoclonal antibody, which blocks the entry of the SARS-CoV-2 virus into healthy cells, is currently being developed for infected patients who don’t need supplemental oxygen and who are at risk of progressing to severe disease.
The European Medicines Agency is currently evaluating sotrovimab in a rolling review. The FDA granted the antibody Emergency Use Authorization in May.